<DOC>
	<DOCNO>NCT00343356</DOCNO>
	<brief_summary>Biochemotherapy ( combine immunotherapeutic drug chemotherapeutic drug ) show virtue use chemical biological drug alone treatment malignant tumor . Here investigated efficacy sequential intravesical therapy EPI BCG EPI BCG alone patient transitional cell carcinoma bladder cancer surgical management .</brief_summary>
	<brief_title>Intravesical Epirubicin Plus BCG Prevent Recurrence Transitional Cell Carcinoma Bladder</brief_title>
	<detailed_description>Methods From July 1996 November 2003 , total 138 case bladder cancer underwent TURBT partial cystectomy enter trail . They divide 3 group randomly : 1 , EPI plus BCG ; 2 , use BCG alone ; 3 , use EPI alone . All patient follow 28-40 month surgery ( average time 36 month ) , frequency bacterial , chemical cystitis local side effect also observed.Results After median follow 36 month , number recurrence group 1 significantly reduce group 2 3 ( p &lt; 0.05 v group 2 3 , x2-test ) . The frequency bacterial , chemical cystitis local side effect similar group 1 2 , whereas significant severe side effect find group 3 ( p &lt; 0.05 v group 2 1 , x2-test ) . Allergic reaction , include skin rash , frequent group 3 , systemic effect frequent group 1 . Conclusion Biochemotherapy single dose EPI plus sequential BCG intravesical markedly effect prevent recurrence bladder cancer surgical management . Its side effect low . This method high clinical value .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>primary single multiple ( 2 tumor ) pTa pT1 transitional cell carcinoma , solitary multiple grade â…¢ tumor primary concomitant carcinoma situ bladder include study Previous radiotherapy , intravesicial systemic chemotherapy within 3 month study , presence second primary malignancy transitional cell carcinoma upper urinary tract prostatic urethra , invasion periurethral prostatic duct , prostatic gland stroma exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>May 1996</verification_date>
	<keyword>Bladder neoplasm ;</keyword>
	<keyword>Carcinoma ;</keyword>
	<keyword>Epirubicin ;</keyword>
	<keyword>BCG ;</keyword>
	<keyword>Perfusion</keyword>
</DOC>